Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Randomized, Double-blind, Active Control Study to Evaluate the Safety and Efficacy of IV Pro-netupitant/Palonosetron (260 mg/0.25 mg) Combination for the Prevention of Chemotherapy-induced Nausea and Vomiting in Repeated Chemotherapy Cycles in Patients Receiving Highly Emetogenic Chemotherapy
Conditions
Interventions
Pro-netupitant/Palonosetron
Netupitant/Palonosetron
+1 more
Locations
74
United States
Sarcoma Oncology Center
Santa Monica, California, United States
The Oncology Institute of Hope and Innovation
Whittier, California, United States
St. Mary's Medical Center
Grand Junction, Colorado, United States
Well Pharma Medical Research Corporation
Miami, Florida, United States
Illinois CancerCare
Peoria, Illinois, United States
Indiana University Health Bloomington
Bloomington, Indiana, United States
Start Date
November 1, 2015
Primary Completion Date
August 1, 2016
Completion Date
August 1, 2016
Last Updated
June 20, 2018
NCT05838638
NCT06331520
NCT02106494
NCT04054193
NCT05841849
NCT01937156
Lead Sponsor
Helsinn Healthcare SA
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions